ARM entered the week after a blowout earnings print facing an unusual split: almost every analyst on the Street was lifting targets sharply higher while Goldman Sachs — the lone vocal bear — raised its Sell target too, but only to $150, less than three-quarters of the current $207.92 price. That divergence is the central tension in the stock right now.
The analyst reaction to the May 6 earnings beat was sweeping. Barclays, TD Cowen, RBC, Wells Fargo, Guggenheim, Keybanc, Rosenblatt, Mizuho, and Evercore ISI all lifted targets within 24 hours of the print, nearly all maintaining Buy or Outperform ratings. Target upgrades ranged from $60 to $130 in a single move — TD Cowen went from $165 to $265, Keybanc from $170 to $300, Evercore from $227 to $326. The mean consensus target now sits at $226.50, implying about 9% upside from here. Goldman, the only named Sell, raised its target from $125 to $150 but remains deeply offside versus consensus. The bull consensus is essentially that ARM's Armv9 royalty ramp, its custom compute systems, and a $330 billion-and-growing cloud AI addressable market justify a premium multiple. Goldman's pushback centres on valuation: the stock trades at 84x trailing earnings and 69x EV/EBITDA, both of which have actually compressed meaningfully over the past week as the price stalled after the post-earnings gap. The 30-day PE move is still +17.6x, a reminder of how far the re-rating has run since April.
Positioning in the lending market tells a much calmer story than the valuation debate would suggest. Availability remains generous — short availability is far from tight, with the borrow market loose and cost to borrow running at just 0.39%, down roughly 13% on the week and nearly 20% over the past month. Shorts added about 2% to their position on the week in share terms, a modest rebuild after a multi-week drift lower, but the 16 million shares short are a fraction of a $221 billion float. The ORTEX short score is 59.5 — moderate, not extreme — and has been flat to slightly lower over the past two weeks, consistent with no meaningful new conviction on either side. Availability at current levels means new short positions face no meaningful friction.
Options positioning has eased back from defensive extremes. The put/call ratio is 1.11, just below its 20-day average of 1.17 — a slight reduction in hedging pressure relative to the recent norm. That 20-day average itself reflects the April trade-war volatility, when the PCR was trading in the 1.30s. It has trended steadily lower since those April highs, matching the stock's 40% one-month rally. The PCR z-score of -0.97 confirms options traders are running slightly less defensive than usual right now, not more. The 52-week range of 0.69–1.35 shows the current reading is firmly in the middle of the historical distribution.
One angle worth noting is the insider activity. CEO Rene Haas sold approximately $1.8 million of shares in mid-April, when the stock was in the $160–$163 range. CFO Jason Child sold $3.8 million at $180 in late April. Both sales came ahead of the earnings catalyst, and the stock has since moved significantly higher. Net insider selling over the 90-day window totals roughly $13.6 million across roughly 83,700 net shares — a steady programme rather than a one-off signal, with trade significance scores uniformly low at 2 out of 10. This pattern is consistent with scheduled executive selling rather than informed conviction.
The next earnings event is not until late July — July 29 — which gives the stock a relatively clear runway from event risk for now. The May 6 print showed a 2.1% one-day move, unremarkable given the 14.7% gap that followed the March 24 release. With EPS 12-month forward YoY increase ranked at the 91st percentile and 90-day EPS momentum at the 81st percentile, the forward earnings revision story remains broadly supportive. What to watch between now and July is whether the re-rating holds at these multiples or whether the valuation compression that began this week — PE down 14x over the past seven days — continues as the post-earnings euphoria fades.
See the live data behind this article on ORTEX.
Open ARM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
